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Synthesis of a Novel COX-2 inhibitor Analog for PET Scan Imaging

Abstract
Tumor imaging is a rapidly growing and important area of medical research. COX-2 is an
enzyme found in large quantities in tumors, and its inhibitors are of special interest as carrier
molecules of radiolabeled atoms for PET scans of the body. Fluorine-18 is a commonly used
PET isotope because its half-life of 110 minutes provides an adequate amount of time to
incorporate it into appropriate PET imaging molecules, but it does not cause as much damage
from radiation as other longer lasting isotopes. The present study describes the synthesis and
radiofluorination

of

a

novel

COX-2

inhibitor

analog,

2-(4-(2-(4-

(methylsulfonyl)phenyl)cyclopent-1-enyl)phenoxy)ethyl methanesulfonate, for use in PET scans
as a potential imaging agent. The synthesis was accomplished first through the creation of a
diaryl heterocycle via two Suzuki coupling reactions and then through the addition of a mesylate
leaving group, which was exchanged with

18

F to give the desired compound. This reaction

scheme resulted in an overall radiochemical yield, non decay corrected, of 11%.
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Chapter 1: Introduction
The inflammatory process is a crucial part of how the body deals with infection and
irregularities in homeostasis.1 Cyclooxygenase (COX), also known as prostaglandin G/H
synthase, is an enzyme which is recruited to the site of inflammation during such a process and
acts by catalyzing the reaction of arachidonic acid to prostanoids such as prostaglandins and
thromboxanes.2 These prostanoids are responsible for downstream effects of many physiologic
responses. COX exists in multiple forms, the most common being the constitutive and induced
forms, termed COX-1 and COX-2 respectively. COX-2 is located primarily in the brain and
kidney and is transiently expressed in response to stimuli such as cytokines, growth factors, and
hormones. COX-2 has also been shown to be overexpressed in many types of cancer.3 COX-1,
however, is normally expressed in most resting tissues and serves a protective function in
maintaining the integrity and homeostasis of the gastric and renal systems.4
Some of the most common drugs which work to reduce pain and the inflammatory
response are the nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and
naproxen, which compete for the active site of COX enzymes and effectively block their
function. However, while the functions of the two forms of COX are different, their structure and
action are very similar. NSAIDs not only block the inflammatory response of COX-2 but also
disrupt the constitutive expression of COX-1.5 Long term COX-1 inhibition and use of NSAIDs
has been found to cause serious health defects especially relating to the gastric tract (stomach
ulcers, etc.), as the protective abilities of COX-1 are suspended.6 Therefore, the need for drugs
which reduce or eliminate these harmful side effects spurred the search for COX-2 selective
inhibitors. The first to be discovered was DuP-697, an anti-inflammatory agent which did not
produce negative gastric side effects.7 It was discovered that, though COX-1 and COX-2 have
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very similar structures, the active site of COX-2 has an extra “pocket” and is slightly larger. The
diaryl heterocyclic structure of DuP-697 was found to fit very well in both the main active site
and the extra “pocket” while having poor affinity for the COX-1 active site.8 The binding
kinetics and selectivity of COX-2 over COX-1 enzymes can be controlled by modifying certain
points in this base structure. It was found that at least one of the phenyl substituents of the
compound should have a sulfonyl or sulfonamide group in the para position for greatest COX-2
selectivity and other sites could be changed as well, including the components of the heterocycle
itself.9 Many such preferential drugs have since been developed using the diaryl heterocyclic
structure as a base, including Celecoxib, Rofecoxib and Valdecoxib, Figure 1. It should be noted
that the structure of these molecules is of great importance since unexpected physiological
responses may occur as observer for Rofecoxib. This drug was taken off the market after studies
showed increased adverse cardiovascular events in patients with coronary artery disease. This is
due to the ability of Rofecoxib to act as a weak base, and easily oxidized.10

Figure 1. Examples of the structures of selective COX-2 inhibitors.

As previously noted, overexpression of COX-2 is involved in cancer. The inflammatory
process is triggered when a cell begins to divide out of control, recruiting a variety of molecules
to the site. COX-2 in particular has been implicated in multiple steps of cancer progression
including its initiation, proliferation, and metastasis. Mechanisms that have been proposed for its
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involvement deal with increased production of PGE2 by the overexpressed COX-2. It has been
shown to be a factor in the effective blockage of programmed cell death and anticancer
treatments, and through the creation of reactive oxygen species which cause DNA damage and
mutations. Increased PGE2 is most often associated with colon, breast, and lung cancers and has
recently been found to be associated with some lymphomas as well.11-13 Radiolabeled COX-2
inhibitors, therefore, are considered to be very effective candidates for visualization of tumors
and cancer metastases.
Positron emission tomography (PET) is a broadly used method of imaging biological and
molecular processes. In particular, it is useful in research and nuclear medicine.14 PET functions
through the use of a radiolabeled molecule such as biologically active small molecules, peptides,
ligands, or enzyme inhibitors which localize at a site of interest. The radioactive atom attached to
the biologically active molecule emits positrons which decay into to photons travelling in
opposite (nearly 180⁰) directions that can be traced back to the point of origin to form an
image.15 Fluorine-18 is a popular radiotracer because of its half-life of 110 minutes, keeping the
radioactive material from lingering too long in the body, and because it can be easily attached to
molecules found normally in the body. Other radioactive elements such as

124

I have also been

studied but are less efficient, have longer half-lives, and produce higher energy gamma rays
which expose patients to higher levels of radiation and decrease the quality of the image.16
The need for a variety of biological molecules which can be easily radiolabeled for PET
imaging has caused a surge in research in this area of nuclear medicine. COX-2 inhibitor analogs
in particular have been of interest because of their presence in tumors. Many of those previously
synthesized had low success rates due to the properties of the molecule chosen or because they
required a large amount of time to incorporate the

18

F into the molecule, reducing their
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effectiveness. This has led to the study of the factors which will increase the success of this
reaction. It has been found that aliphatic nucleophilic substitutions of

18

F into target molecules

are particularly useful, efficient, and easy to prepare if a good leaving group such as a halogen or
sulfonate is present in the molecule.16 Sulfonic acid esters (such as tosylate or mesylate
functionalities) have high reactivity and can be easily synthesized without threatening the
structural integrity of the molecule. In addition to modifying and optimizing the site of reaction,
the base molecule can be modified to make the reaction easier. In particular, 1,2diarylcyclopentenes and their derivatives have shown to be effective structural motifs in COX-2
inhibitors by having increased selectivity over COX-1 inhibitors.18
The present study aims to improve upon the radiolabeling procedure presented by Laube,
et al.19 in which a ditosylate is first radiolabeled with
methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol

18

F and then attached to 4-(2-(4-

(compound

6). This

method, though

successful, is lengthy, and limits the time available from when the radiotracer is incorporated
into the molecule to the time of use. By synthesizing the radiolabeled precursor in its entirety
before incorporating the 18F, it is hypothesized that a higher radiochemical yield can be obtained.
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Chapter 2: Experimental Procedure
2.1 Synthesis Overview
The synthesis of the precursor molecule 7 for radiolabeling is shown in the reaction
scheme presented in Figure 2 below. It was carried out in four steps, involving the creation of a
1,2-diarylcyclopentene through two Suzuki cross-coupling reactions, the conversion of the
methoxy group to a hydroxyl moiety, and finally the addition of the bromoethyl
methanesulfonate. The general procedure used was based on a modification of that given by
Wuest, et al.20 All non-radioactive compounds were purified by flash chromatography as
outlined by Still, et al21 and analyzed by 1H-NMR spectroscopy. Precursor 7 was then labeled
with 18F. The radiolabeled compound 8 was analyzed by radio-TLC (see appendix for spectra).

Figure 2. Overall reaction scheme for synthesis of precursor for radiolabeling, compound 7.

10

2.2 Synthesis of 1-(2-Bromocyclopent-1-enyl)-4-methoxybenzene (3)
The starting materials, 1,2-dibromocyclopentene, 1, (1.0 g, 4.4 mmol) and 4methoxyphenyl boronic acid 2 (336 mg, 2.20 mmol) were added to a roundbottomed flask.
Toluene, ethanol, and 2M sodium carbonate were then added in a 1:1:1 ratio using 30 mL of each
reagent. The roundbottomed flask was then capped and vacuum was applied for 15 minutes to
remove any dissolved oxygen. The Pd(PPh3)4 catalyst (127 mg, 0.110 mmol) was then carefully
added with the resulting solution placed under argon atmosphere and refluxed for 2 hours at 90
⁰C with stirring. The reaction progress was monitored by thin layer chromatography (TLC, 50%
ethyl acetate/hexanes) every 30 minutes until completion. After the reaction was complete, 250
mL of water was added and the product solution was extracted with ethyl acetate. The ethyl
acetate extract was then dried over anhydrous sodium sulfate and a rotary evaporator was used to
remove the solvent. The residue was then purified by flash chromatography (50% ethyl
acetate/hexanes), checking for the presence of the desired compound 3 in each fraction by TLC.
The fractions containing 3 were then placed on the rotary evaporator to give 330 mg of a yellow
oil. The reaction yield was 59% based on compound 2.

Figure 3. Reaction scheme for first Suzuki coupling reaction.
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2.3 Synthesis of 1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1enyl)-benzene (5)
The starting materials 1-(2-bromocyclopent-1-enyl)-4-methoxybenzene, 3, (300 mg, 1.18
mmol) and 4-(methylsulfonyl)phenylboronic acid 4 (236.8 mg, 1.18 mmol) were added to a
roundbottomed flask. Toluene, ethanol, and 2M aqueous sodium carbonate were then added in a
1:1:1 ratio of 16 mL each. The roundbottomed flask was then capped and placed under vacuum
for 15 minutes to remove any dissolved oxygen. The Pd(PPh3)4 catalyst (70 mg, 0.06 mmol) was
then carefully added with the resulting solution placed under argon atmosphere and refluxed for
1 hour at 90 ⁰C with stirring. The reaction progress was monitored by TLC (50% ethyl
acetate/hexanes) every 30 minutes until completion. After the reaction was complete, 100 mL of
water was added and the product solution was extracted with ethyl acetate. The ethyl acetate
extract was then dried over anhydrous sodium sulfate and a rotary evaporator was used to
remove the solvent. The residue was then purified by flash chromatography (50% ethyl
acetate/hexanes), checking for the presence of the desired compound 5 in each fraction by TLC.
The fractions containing 5 were then placed on the rotary evaporator to give 112 mg of a
white/yellow solid with a melting point of 128-130 ⁰C. The reaction yield was 29%.

Figure 4. Reaction scheme for second Suzuki coupling reaction.
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2.4 Synthesis of 4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol
(6)
1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1-enyl)-benzene, 5, (112 mg, 0.34
mmol) was dissolved in 1.3 mL of dichloromethane in a stirring roundbottomed flask. The
mixture was cooled to -78 ⁰C in a dry ice/acetone bath and 1M boron tribromide in
dichloromethane (0.39 mL, 0.39 mmol) was added, turning the solution brown. The solution was
then warmed to room temperature and allowed to stir for one hour, monitoring the reaction
progress by TLC (30% ethyl acetate/hexanes). The solution was again cooled to -78 ⁰C using a
dry ice/acetone bath and 0.65 mL of methanol was added, turning the solution a dark green,
before warming the mixture to 0 ⁰C in an ice water bath for an additional hour. The solvent was
then evaporated using a rotary evaporator and the compound was purified by flash
chromatography (30% ethyl acetate/hexanes), checking for the presence of the desired compound
6 in each fraction by TLC. The fractions containing 6 were then placed on the rotary evaporator
to give 48 mg of a solid with a melting point of 154-156 ⁰C. The reaction yield was 45%.

Figure 5. Reaction scheme for synthesis of phenol intermediate.
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2.5 Synthesis of 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1enyl)phenoxy)ethyl methanesulfonate (7)
4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol, 6, (48 mg, 0.15mmol) was
dissolved in a roundbottomed flask in 5 mL of acetone. Cesium carbonate (73.3 mg, 0.225
mmol) and 2-bromoethyl methanesulfonate (45 mg, 0.23 mmol) were then added and the
resulting solution was placed under argon atmosphere and refluxed and stirred at 50 ⁰C in an oil
bath for 3 hours. The reaction progress was monitored by TLC (20% ethyl acetate/hexanes)
every 30 minutes until completion. The resulting product was then put on a rotary evaporator to
remove the solvent. The residue was then purified by flash chromatography (20% ethyl
acetate/hexanes), checking for the presence of the final compound 7 in each fraction by TLC.
The fractions containing 7 were then placed on the rotary evaporator to give 17 mg of a liquid.
The reaction yield was 26%.

Figure 6. Reaction scheme for addition of bromoethyl methanesulfonate to the phenol
intermediate.
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2.6 Synthesis of 1-(2-(Fluoro-18F)ethoxy)-4-(2-(4(methylsulfonyl)phenyl)cyclopent-1-enyl)benzene (8)
The

final

step

in

this

reaction

scheme

involves

the

radiolabeling

of

precursor 7 with fluorine-18. 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1-enyl)phenoxy)ethyl
methanesulfonate 7 (4.0 mg, 9.2 µmol) was dissolved in t-amyl alcohol (0.75 mL), acetonitrile
(0.083 mL) and DMF (0.17 mL) before adding a Kryptofix-2.2.2, potassium carbonate, and
[18F]fluoride to the mixture. The radiofluorination was carried out at 100⁰C for 20 minutes.
Unreacted fluoride was then removed by adding 5 mL of water to the reaction and passing it
through an alumina N Sep-Pak cartridge. A radio-TLC of the product was carried out in 60%
ethylacetate/40% hexanes and determined an overall non-decay corrected radiochemical yield of
11% (12.5% decay corrected).

Figure 7. Reaction scheme for the addition of 18F to the mesylated precursor.
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Chapter 3: Discussion and Conclusions
The synthesis of compound 8 was successfully completed using the method described
above. However, a few revisions from the originally planned experimental procedure were
necessary for the complete synthesis of 8.
The Suzuki coupling reaction steps for synthesis of 3 and 5 were originally planned to
utilize refluxing conditions for 24 hours as described by Wuest, et al. However, TLC analysis
during the first two hours of each reaction showed that the reactants were consumed and a
product was formed. The reaction was allowed to run for the full 24 hours, but all of the desired
product was completely dehalogenated upon spectral analysis, indicating too long of a reaction
time. The reaction was run again and monitored very carefully by TLC, and was stopped after 2
hours when all reactant was converted to product. This unexpected phenomenon was likely due
to the removal of dissolved oxygen before adding the catalyst during this experiment, a step
which

was

not

outlined

in

the

paper

by

Wuest,

et

al.

The

tetrakis(triphenylphosphine)palladium(0) catalyst is highly sensitive to oxygen and light and is
not optimally active when these factors are present.22 This is believed to be the reason for the
better action of the catalyst and therefore the faster reaction time during the present experiment.
Another complication encountered during the experiment was in the synthesis of 7. As
the purpose of this experiment was to improve upon the radiolabeling method presented by
Laube, et al., the same leaving group, ethylen-1,2-ditosylate, was originally used during the
synthesis of 7. However, upon spectral analysis, there was no evidence of the correct product 7
and excess ditosylate was found to be present. This led to the conclusion that 6 reacted twice
with the ditosylate, displacing both tosylate groups and creating an undesired product. This
possibility was considered during the experimental design and to be avoided by using 2.5
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equivalents of the ditosylate as compared to 6, but this did not appear to have stopped the
undesired reaction from occurring. Consequently, 2-bromoethyl methanesulfonate was used in
place of the ethylen-1,2-ditosylate. This compound functions in the same manner as the
ditosylate but since only one end of the molecule has the more reactive sulfonic acid ester for
radiofluorination, the aforementioned problem was not encountered. The mesylate group has
actually been found to be a more reactive leaving group than the tosylate group in

18

F-

fluorinations and therefore was chosen as a useful substitute for the present experiment.16
The radiochemical yield (RCY) of 8 was 11% non-decay corrected. Previous attempts at
creating 8 via a different method as presented by Laube, et al resulted in a decay-corrected RCY
of 7.8%, which translates to 4.7% non-decay corrected RCY after 80 minutes as described.19
This demonstrates that the new method more than doubled the non-decay RCY and is thus
provides a more efficient means of producing this compound. In general, the yields of the nonradioactive reaction steps were lower than expected, especially when compared to those reported
by Wuest. This is likely due human error during steps such as extraction and purification by flash
chromatography. However, in chapter 2.5, the poor yield of 26% is likely due to a mixture of
products formed due to the leaving group capacity of both bromine and the mesylate group. It
should be noted that the radio-TLC of compound 8 has a small impurity at 20 mm which was
identified as a trace of the unreacted fluoride that went through the alumina cartridge.
While many molecules for PET scan imaging are already available, there is a growing
demand for easier and more efficient processes by which to incorporate the precursors into radiolabeled compounds. By synthesizing compound 6 in its entirety before fluorinating it with

18

F,

the RCY was greatly increased from the previous method of synthesis as described by Laube, et
al and others in the literature. The improvement allows for a larger window of time from the end
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of synthesis to potential use as a PET scan imaging agent. The present study cannot predict how
effective compound 8 will be in vivo. It is hoped that future studies with this COX-2 inhibitor
analog will determine its efficacy in preclinical trials on small animals such as rats to see how
well the compound mimics COX-2 inhibitor activity. While there are several steps involved in its
synthesis, the ease of the process combined with the advantages noted above provide a promising
method for producing another COX-2 inhibitor analog for PET scan imaging.
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Appendices
Appendix I: NMR Spectra

Spectrum 1. Proton NMR of 1-(2-Bromocyclopent-1-enyl)-4-methoxybenzene, compound 3, at
300MHz.
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Spectrum 2. Proton NMR of 1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1-enyl)benzene, compound 5, at 300 MHz.
23

Spectrum 3. Proton NMR of 4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol,
compound 6, at 300 MHz.
24

Spectrum 4. Proton NMR of 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1enyl)phenoxy)ethyl methanesulfonate, compound 7, at 300 MHz.
25

Spectrum 5. Proton NMR of the Non-radioactively Labeled Compound 8, at 300 MHz.
26

Appendix II: Radio TLC

Spectrum 6. Radio TLC of 1-(2-(Fluoro-18F)ethoxy)-4-(2-(4-(methylsulfonyl)phenyl)cyclopent1-enyl)benzene, Compound 8.
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